SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
OTLK

Outlook Therapeutics, Inc. (NASDAQ:OTLK)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.39-$0.01 (-2.74%)
 
Market cap
$94.9M
Insider Score
Analyst consensus
Listed since
Jun 14, 2016
Market Cap$94.94M-78.3%
Revenue (ttm)n/a-177.3%
Net Incomen/a-40.7%
EPSn/a-7.8%
Shares Out243.45M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume5,181,091
Open$0.40
Previous Close$0.40
Day's Range$0.36 - $0.40
52-Week Range$0.16 - $2.54
Beta0.71
AnalystsBuy
Price Target$2.80(+617.95%)
Earnings Daten/a

About OTLK

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Address
111 S. Wood Avenue, Iselin, NJ, 08830, US
Market Cap
95 million
Employees
17
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$7.91M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $1.30 (+233.3%)

1 firm rating OTLK in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-2.74%
5 Days
-5.57%
1 Month
-30.79%
6 Months
+25.85%
1 Year
-78.33%

$OTLK stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in OTLK holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by OTLK's directors and management

Net Shares Purchased by Insiders−10M−5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

OTLK Estimated quarterly lobbying spending

Source: U.S. Senate LDA

OTLK Revenue by Segment

$5.08MTotal
ONS-5010/LYTENAVA development$2.19M43.08%
Professional fees$1.17M23.12%
Facilities, fees and other related costs$1.09M21.38%
Compensation and related benefits$567.19K11.17%
Stock-based compensation$63.27K1.25%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New OTLK patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to OTLK from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in OTLK

VTIVanguard Morningstar Total Stock Market ETF$2.56M
VXFVanguard Extended Market ETF$880.19K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from OTLK’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
53.85
Analyst Ratings
40% of score
85
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
8
Sells
0
Buy Value
$7.91M
Distinct Buyers
6

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.